Poster #30

Joseph V. Pergolizzi, Jr., MD;¹ Robert B. Raffa, PhD;^{2,3} Peter Magnusson, MD;^{4,5} Jo Ann LeQuang, BA;¹ Charles Wollmuth BS;¹ Robert Taylor, Jr., PhD;¹ Rohit Nalamasu, DO;⁶ Robert Colucci, PharmD;^{1,7} Kailyn Mitchell, MD;¹ Maninder Chopra, MD;⁸ Giustino Varrassi, MD;⁹ and Frank Breve, PharmD^{1,10}

¹NEMA Research, Inc., Naples, Florida; ² Professor emeritus, Temple University School of Pharmacy, Temple University, Philadelphia, Pennsylvania; ³Adjunct professor, University of Arizona College of Pharmacy, Tucson, Arizona; ⁴Centre for Research and Development, Region Gävleborg/Upssala University, Gävle, Sweden; ⁵Department of Medicine, Cardiology Research Unit, Karolinska Institutet, Stockholm, Sweden; ⁶Department of Physical Medicine and Rehabilitation, University of Nebraska Medical Center, Omaha, Nebraska,; ⁷Colucci & Associates, LLC, Newton, Connecticut; ⁸Decision Alternatives, LLC, Frederick, Maryland; ⁹Paolo Procacci Foundation, Rome, Italy; ¹⁰ Department of Pharmacy Practice, School of Pharmacy, Temple University, Philadelphia, Pennsylvania

PURPOSE

- In 2018, 67% of all opioid-related deaths in the United States traced back to synthetic opioids, mainly fentanyl.¹ Synthetic drugs are made for any number of reasons, including superior pharmacological attributes, but drugs with abuse potential such as opioids may result in synthetic products to appeal specifically to the illicit market. So ubiquitous are illicit fentanyl analogs collectively they are that termed "nonpharmaceutical fentanyl" (NPF) to distinguish them from pharmaceutical-grade fentanyl, a powerful anesthetic and analgesic drug. NPFs were first observed in street drugs from 2005 to 2007, all traced back to a single clandestine laboratory; when the lab was closed in 2007, NPF trade stopped, but not until more than 1,000 NPF-related deaths had occurred.² Since that time, more clandestine laboratories have opened and NPF reappeared in the streetdrug stream in 2010 as an additive to heroin and cocaine, as a product on its own, or as the active ingredient in counterfeit opioid analgesic tablets or counterfeit benzodiazepines. While the first fentanyl analog (AMF) was produced by Janssen Pharmaceutica in the 1960s, today numerous fentanyl products are on the market or being developed. The original analogs of fentanyl were developed for specific uses, such as veterinary medicine for large animals (carfentanil).³
- Each novel agent represents a major new challenge to drug enforcement as the specific formulation may not be known to medicine or law enforcement, may not technically be illegal or scheduled as a controlled substance, and may not be testable using available testing options. The purpose of our review was to revisit an important topic relevant to the opioid overdose crisis.

- heroin.⁸

Act	History	Nation or organization	rio a result, analog
Commission of Narcotic Drugs, part of the UN Office on Drug and Crime	Created in 1946 to help apply and enforce international drug control treaties	UN	 NPF drugs can enter the street drug trade with a quasi-legal status. They are not detectable until they are identified and appropriate tests are developed. Furthermore, it
Single Convention on Narcotic Drugs	Created in 1961, an international treat to use international enforcement to address drug abuse but it is not self-enforcing (that is, countries must enact laws to carry it out)	International treaty that identifies 77 synthetic opioids as Schedule I drugs	
European Monitoring Centre for Drug and Drug Addiction (EMCDDA)	Classifies drugs, largely follows UN guidance	European Union	
Federal Analogue Act	Passed in 1986, this law was intended to speed scheduling of dangerous analog substances	United States	• Furthermore, 1t seems that novel fentanyl analogs are
Controlled Drug and Substances Act	Set up in 1996 and classifies fentanyl analogs as Schedule I controlled substances	Canada	produced very rapidly, introduced
Misuse of Drugs Act (MDA)	Amended in 1987 and classified fentanyl analogs as a Part 1 Class A drug	United Kingdom	into the street trade, and then supplanted by
STRIDA project	Monitoring system for novel psychoactive substances; frequently reports on fentanyl analogs	Sweden	newer products.

Nonpharmaceutical Fentanyl Analogs in the Illicit Drug Trade: Where are We Heading?

RESULTS

Fentanyl has been and remains the driver of the increased opioid-overdose mortality in the United States and it appears that fentanyl is likewise driving such mortality trends in Europe as well.⁴ While fentanyl-related overdose deaths are increasing markedly, it is likely they are under-reported as many NPF drugs go undetected either because there is no currently available test for them or the decedent has taken other drugs which are blamed for the death. Street drug users are often unaware that the drugs sold to them as cocaine, heroin, benzodiazepines, or prescription oxycodone tablets are laced with NPF.

• NPF is not used to "cut" or "stretch" drugs like heroin, because NPF is highly potent, in fact, often many times more potent than morphine. Instead, heroin may first be cut with some other substance such as sugar, baking soda, or even laundry detergent or rat poison to increase the quantity.⁵ Small amounts of fentanyl are added to boost the psychoactive effects. The economics behind this are clear: it can cost upward of \$65,000 to produce one kilogram of heroin but just \$3,500 for the same amount of fentanyl.^{6,7} The intrusion of fentanyl into the nation's heroin supply tends to be geographically limited to areas east of the Mississippi River where white heroin is more common than the West Coast's black tar

Fentanyl analogs have a unique chemical composition and as new agents, they are not necessarily controlled substances. As early as 1986, Congress passed the U.S. Federal Analogue Act, an addendum to the U.S. controlled Substances Act which allowed for "substantially similar" Schedule I and II agents to be treated as such, but this has not always been well supported in the courts. ³ See Table 1 below.

- addressed.

- 25, 2020.
- A):121-132.
- 4. **Enforcement Agency.** 2019.
- 6.

Disclosures: JVP discloses the following relationships: Consultant/ Speaker and Researcher for US World Meds, BDSI, Salix, Enalare, Scilex, Pfizer, Lilly, Teva, Regeneron, Redhill, Grunenthal, and Neumentum. The other authors have nothing to disclose.

PAINWeek * Las Vegas, NV * September 8-12 (Virtual Meeting)





CONCLUSIONS

• The rapid development and proliferation of highly potent and dangerous fentanyl analogs poses an ongoing international public health crisis. Improved methods are needed to rapidly identify these agents and develop tests for them. Better education is needed for harm reduction among those who use illicit drugs, as NPF can be added to products without the knowledge or consent of the buyer.

• More readily available and accessible testing is needed so that the opioid-overdose mortality attributable to NPF analogs can be better quantified and, in that way, more effectively

REFERENCES

Centers for Disease Control and Prevention. Synthetic Opioid Overdose. Centers for Disease Control and Prevention,. Opioid Overdose Web site. https://www.cdc.gov/drugoverdose/data/fentanyl.html. Published 2020. Updated March 19, 2020. Accessed June

2. Jones TS, Krzywicki L, Maginnis J, et al. Nonpharmaceutical Fentanyl-Related Deaths - Multiple States, April 2005-March 2007. MMWR Morbidity and Mortality Weekly Report, Jul 25, 2008, Vol57(29), pp793-6. 2008. Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134(Pt

DEA. 2017 National Drug Threat Assessment. Drug https://www.dea.gov/sites/default/files/2018-07/DIR-040-

17_2017-NDTA.pdf. Published 2017. Accessed May 20,

Houck J, Ganti L. A Local Epidemic of Laced Heroin Causing Skin Necrosis. *Cureus.* 2019;11(5):e4782-e4782. Gladden RM, Martinez P, Seth P. Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014. MMWR Morb *Mortal Wkly Rep.* 2016;65(33):837-843. Frank RG, Pollack HA. Addressing the Fentanyl Threat to Public Health. N Engl J Med. 2017;376(7):605-607.